GO
| HSI1 | 23,753.84 | 0.00 | -- |
| HSCEI1 | 7,981.54 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-11-16 17:34:36 Morgan Stanley published a research report stating that the results of this year's National Reimbursement Drug List have been announced. The commercial catalog added 12 innovative drugs from 11 companies, with a 100% success rate, higher than last year's 79%, bringing the total to 28 drugs. Another two drugs were transferred into the basic medical insurance catalog. A total of 107 drugs were newly added to the reimbursement drug list, including a record-high 51 Class 1 innovative drugs, with a success rate of 86%, compared with 88% last year. The newly included drugs cover oncology, rare diseases, chronic diseases and psychiatric disorders. Meanwhile, 34 drugs with limited clinical value were removed from the catalog, bringing the total number of listed drugs to 3,331. Among them, Relma-cel became the first CAR-T cell therapy to enter the basic medical insurance catalog, with the price sharply reduced from RMB1.29 million per injection to RMB288,600 per injection. This move may pave the way for more CAR-T therapies to be included in medical insurance coverage in the future. The broker rated China's healthcare sector as "Accumulate". (sl/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |